Genetic Technologies (FRA:DU8) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Genetic Technologies COGS-to-Revenue?

Genetic Technologies's Cost of Goods Sold for the three months ended in Jun. 2024 was €0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was €0.00 Mil.

Genetic Technologies's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Genetic Technologies's Gross Margin % for the three months ended in Jun. 2024 was N/A%.

Genetic Technologies COGS-to-Revenue Historical Data

The historical data trend for Genetic Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies COGS-to-Revenue Chart

Genetic Technologies Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

COGS-to-Revenue

Get a 7-Day Free Trial

6.17

1.42

0.44

0.50

0.49

Genetic Technologies Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Genetic Technologies COGS-to-Revenue Calculation

Genetic Technologies's COGS to Revenue for the fiscal year that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.32	/	4.728
	=	0.49

Genetic Technologies's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Genetic Technologies (FRA:DU8) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Genetic Technologies's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Genetic Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (FRA:DU8) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies Headlines

No Headlines